MAOIs & antidepressants which affect noradrenagic transmission (eg, TCAs & mianserin). Ocular hypotensive response may be blunted by TCAs. Additive or potentiating effect w/ CNS depressants (eg, alcohol, barbiturates, opiates, sedatives or anaesth). Drugs which can affect metabolism & uptake of circulating amines (eg, chlorpromazine, methylphenidate, reserpine, serotonin-norepinephrine reuptake inhibitors). Concomitant use w/ antihypertensives &/or cardiac glycosides; agonists or antagonists of the adrenergic receptor (eg, isoprenaline, prazosin). Acid-base disturbances w/ oral carbonic anhydrase. Brinzolamide metabolism may be inhibited by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clotrimazole, ritonavir & troleanclomycin).